Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not?

Vivian G. Szeto^1,2, Justine Y. Ye¹, Vinod Chandran³, Dafna D Gladman⁴ and Cheryl F. Rosen⁵, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: psoriasis, psoriatic arthritis and research methods

Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of people with psoriasis. The current understanding of these diseases involves patients who agree to participate in clinical studies. Therefore, it is not clear whether or not information gained from these studies is generalizable to all patients with psoriatic disease. The aim of this study was to determine whether the clinical features and outcomes of psoriatic disease patients who participate in clinical research are the same as those who do not.

Methods:

Two cohorts of research patients were studied: patients with psoriatic arthritis (PsA cohort) and patients with psoriasis without psoriatic arthritis (PsC cohort). The PsA and PsC cohorts are defined as patients enrolled in clinical research whose follow-up assessments are based on a standardized protocol. A third cohort was studied which included patients who are not enrolled in research (Clinic cohort).

The information on the patients’ disease history (age of onset, extent of psoriasis), demographic and social history (gender, smoking, employment), medication (past and current), and comorbidities (cardiovascular, respiratory, autoimmune) was collected from their charts. The Clinic cohort information was compared to both the PsA and PsC cohorts using one-way ANOVAs, Pearson’s Chi – square, and logistic regression analysis to test association of variables.

Results:

A total of 200 patients were included in each cohort studied. Of the 200 patients collected in the Clinic Cohort, 46 patients had PsA while 154 patients did not. The Clinic Cohort data was subsequently split into a PsA Clinic cohort and Psoriasis Clinic cohort to be compared to their respective research cohorts.

The average age of PsA patients studied was 53.3 for the Clinic cohort and 51.0 for the PsA cohort; whereas the average age of PsC patients included in the study was 52.0 for the Clinic cohort and 55.5 for the PsC cohort. The psoriasis disease duration varied among the cohorts with the average being 13.1 y for the PsA Clinic Cohort, 21.6 y for PsA cohort, 17.0 y for the Psoriasis Clinic cohort and 22.9 y for the PsC cohort. In terms of the comorbidities, 32% of the PsA Clinic cohort and 29% of PsA Cohort have cardiac disease while 32% of Psoriasis Clinic Cohort and 33% of the PsC Cohort have been diagnosed with heart disease. Analysis of the therapies and outcomes of the three cohorts is underway.

Table 1. Comparison of the demographic, social history variables, comorbidities and clinical features between the Clinic cohort and the research cohorts (PsA cohort and PsC cohort). The demographic and social variables were statistically analyzed using the Chi-square distribution. The Pearson’s Chi-square test was performed on the comorbidities variables while an One-way ANOVA was used to analyze the clinical features, * significant difference at p < 0.05.
		PsA Cohort vs. PsA Clinic Cohort	PsC Cohort vs. Psoriasis Clinic Cohort
	Variables	p-value	p-value
Demographic & Social History Variables	Gender	0.2456	0.7796
	Smoking	0.0216*	0.0084*
	Employment	0.8474	0.4318
Comorbidities	Cardiovascular	0.63	0.92
	Respiratory	0.13	0.45
	Autoimmune	0.08	<0.001*
Clinical Features	Average Age of Patients in the Study	0.33	0.022*
	Average Age of Psoriasis Diagnosis	<0.001*	0.22
	Psoriasis Disease Duration	<0.001*	<0.001*

Conclusion:

These preliminary results show similarities between the research cohorts and the cohort of patients not involved in clinical research, suggesting generalization of the results of clinical research to all patients with psoriatic disease may be possible. Patients are still being actively recruited to the Clinic Cohorts.

Disclosure: V. G. Szeto, None; J. Y. Ye, None; V. Chandran, None; D. D. Gladman, None; C. F. Rosen, None.

To cite this abstract in AMA style:

Szeto VG, Ye JY, Chandran V, Gladman DD, Rosen CF. Do Psoriatic Disease Patients Who Participate in Clinical Research Differ from Those Who Do Not? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/do-psoriatic-disease-patients-who-participate-in-clinical-research-differ-from-those-who-do-not/. Accessed .

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-psoriatic-disease-patients-who-participate-in-clinical-research-differ-from-those-who-do-not/